# Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy

> **NCT04984876** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 211 (actual)

## Conditions studied

- Allergy, Peanut

## Interventions

- **DRUG:** ligelizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04984876
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-07
- **Primary completion:** 2023-11-27
- **Final completion:** 2023-11-27
- **Target enrollment:** 211 (ACTUAL)
- **Why stopped:** Study terminated by sponsor
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04984876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04984876, "Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04984876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*